Innoviva Shares Outstanding 2006-2020 | INVA

Innoviva shares outstanding from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Innoviva Annual Shares Outstanding
(Millions of Shares)
2019 113
2018 113
2017 120
2016 123
2015 115
2014 112
2013 102
2012 91
2011 82
2010 72
2009 63
2008 61
2007 60
2006 59
2005 53
Innoviva Quarterly Shares Outstanding
(Millions of Shares)
2020-06-30 114
2020-03-31 114
2019-12-31 113
2019-09-30 113
2019-06-30 113
2019-03-31 113
2018-12-31 113
2018-09-30 113
2018-06-30 113
2018-03-31 114
2017-12-31 120
2017-09-30 120
2017-06-30 120
2017-03-31 120
2016-12-31 123
2016-09-30 122
2016-06-30 124
2016-03-31 113
2015-12-31 115
2015-09-30 116
2015-06-30 115
2015-03-31 115
2014-12-31 112
2014-09-30 113
2014-06-30 111
2014-03-31 110
2013-12-31 102
2013-09-30 106
2013-06-30 98
2013-03-31 96
2012-12-31 96
2012-09-30 95
2012-06-30 89
2012-03-31 92
2011-12-31 82
2011-09-30 82
2011-06-30 82
2011-03-31 81
2010-12-31 72
2010-09-30 74
2010-06-30 73
2010-03-31 65
2009-12-31 63
2009-09-30 63
2009-06-30 63
2009-03-31 62
2008-12-31 61
2008-09-30 62
2008-06-30 61
2008-03-31 61
2007-12-31 60
2007-09-30 61
2007-06-30 60
2007-03-31 60
2006-12-31 59
2006-09-30 60
2006-06-30 59
2006-03-31 57
2005-12-31 53
2005-09-30 53
2005-06-30 53
2005-03-31 53
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.100B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $380.285B 18.12
Roche Holding AG (RHHBY) Switzerland $307.223B 0.00
Merck (MRK) United States $208.991B 14.91
Novartis AG (NVS) Switzerland $200.147B 15.56
Pfizer (PFE) United States $200.048B 12.50
Novo Nordisk (NVO) Denmark $163.423B 26.59
AbbVie (ABBV) United States $153.788B 9.37
AstraZeneca (AZN) United Kingdom $146.073B 28.40
Eli Lilly (LLY) United States $143.289B 21.87
Sanofi (SNY) $126.734B 15.06
GlaxoSmithKline (GSK) United Kingdom $94.797B 12.43
Bayer (BAYRY) Germany $59.441B 8.57
H Lundbeck (HLUYY) Denmark $6.468B 11.24